Breast Cancer Clinical Trials

Showing 2301-2320 of 4,817 trials

Efficacy of Cilostazol in Prevention of Peripheral Neuropathy

NCT05298696

There are several mechanisms concerning pathophysiology of paclitaxel induced peripheral neuropathy. One of the main mechanisms is induction of Schwann cell dedifferentiation by paclitaxel. At the preclinical level, cilostazol potently inhibited paclitaxel-induced dedifferentiation of cultured Schwann cells, yet this positive effect have not been clinically investigated.

Peripheral NeuropathyBreast Cancer

Mansoura University71 participantsStarted Mar 2022

Al Mansurah, Egypt

COMPLETEDPhase 1

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

NCT04584112

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of tiragolumab in combination with atezolizumab and chemotherapy in participants with metastatic and early triple-negative breast cancer (TNBC).

Triple-Negative Breast Cancer

Hoffmann-La Roche83 participantsStarted Sep 2020

Birmingham, Alabama, United States • Chicago, Illinois, United States • Charlotte, North Carolina, United States +21 more locations

Efficacy of Cilostazol in Prevention of Peripheral Neuropathy

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Related Searches

Ultrasound Radiomics for Predicting Breast Cancer and Axillary Lymph Node Metastasis

Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Comparison of the Efficacy and Tolerability of Femal Versus Placebo

Immunological Variables Associated to ICI Toxicity in Cancer Patients

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx

Satisfaction Survey for the Outpatient Unit Dedicated to Post-cancer Treatment

Autohypnosis and Cancerology

Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.

Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

Retrospective Observational Study About Evolution of Patients With Breast Cancer in Hospitals From GEICAM Group

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Reliability and Reproducibility of Bandaging in Breast Cancer

TAC Versus TC for Adjuvant Breast Cancer